• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

New Study Looks at Shame, Guilt and the Psychedelic Experience

Microdose NewsDesk by Microdose NewsDesk
November 27, 2023
in Science
Reading Time: 1 min read
A A
New Study Looks at Shame, Guilt and the Psychedelic Experience

A new study published by a group of researchers, including Matthew Johnson from Johns Hopkins, looks at emotionally painful, shame-related processes with psychedelic use.

The surveys collected data from 679 adults planning to use psilocybin before and after psilocybin use. Shame and feelings of guilt were collected using validated reporting measures and assessed alongside other measurements of psychological health.

Results: Most users (89.7%) described their experience of psilocybin as positive, though acute feelings of shame or guilt were commonly reported (68.2% of users) and were difficult to predict. Psilocybin on average produced a small but significant decrease in trait shame that was maintained 2-3 months after use. Trait shame did increase in a large minority (29.8%) of participants.

See the complete study here:

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use

Order Affordable Lasix

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

 

Source: https://osf.io/preprints/psyarxiv/hm6jn/?utm_source=tricycleday&utm_medium=newsletter&utm_campaign=this-week-in-psychedelics
[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: psilocybin
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Enveric Granted US Patent for Psilocybin Derivatives

Enveric Granted US Patent for Psilocybin Derivatives

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.